Study identifier:SH-QBE-0015
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
A multicenter, randomized, double-blind, six-month maintenance study to compare the efficacy, safety and tolerability of H 199/18 40 mg, H 199/18 20 mg, and H 199/18 10 mg with placebo in healed erosive esophagitis subjects
gastrointestinal diseases
N/A
-
-
-
-
Interventional
-
Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
Verified 01 Nov 2013 by AstraZeneca
AstraZeneca
-
No locations available
Arms | Assigned Interventions |
---|